Cardinal Health had its Relative Strength (RS) Rating upgraded from 65 to 71 Thursday — a welcome improvement, but still below the 80 or better score you look for.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an 80 or better RS Rating as they begin their biggest runs. See if Cardinal Health can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Cardinal Health is now considered extended and out of buy range after clearing a 116.05 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 9% earnings growth last quarter. Sales rose -4%.
The company holds the No. 4 rank among its peers in the Medical-Wholesale Drugs industry group. is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
